Indivior Pharmaceuticals (INDV) is back in focus after a recent period of strong longer term returns, with the stock up about 195% over the past year and about 102% over the past 3 months.

Recent trading has cooled slightly, with the share price down about 1% over the past day and about 2% over the week. However, the 30 day share price return of 6% sits alongside a very strong 1 year total shareholder return of 195%. This suggests momentum has been building over a longer horizon even as short term sentiment consolidates around the latest US$36.61 level.

If Indivior Pharmaceuticals has caught your attention, it could be a good moment to broaden your search and check out 35 healthcare AI stocks

With Indivior Pharmaceuticals trading at about a 41% discount to the current analyst price target and an estimated intrinsic discount of around 66%, you have to ask: is there still real upside here, or is the market already pricing in future growth?

Most Popular Narrative: 3.3% Undervalued

Indivior Pharmaceuticals most followed narrative pegs fair value at about $37.86 per share, only slightly above the last close of $36.61, which keeps the story finely balanced.

The multiyear Indivior Action Agenda, including at least $150 million in annual operating expense savings and a capped 2026 operating budget of $450 million, is intended to materially lower the cost base and support the translation of revenue growth into earnings and cash flow expansion.

Want to see what turns modest revenue assumptions into a higher fair value? The narrative leans on expanding margins and a future earnings profile that looks very different from today.

Result: Fair Value of $37.86 (UNDERVALUED)

However, there are still clear risks, including weaker than expected SUBLOCADE uptake or cost savings that fall short. Both of these could challenge this undervaluation story.

Another View: Earnings Multiple Sends A Different Signal

The discount implied by fair value models sits uncomfortably beside the current P/E of 17.7x, which is higher than the US Pharmaceuticals industry at 15.4x and above the fair ratio of 17.3x. That small but clear premium suggests less margin for error if expectations slip.

For a closer look at how this P/E premium compares to both peers and the fair ratio in detail, check out the See what the numbers say about this price — find out in our valuation breakdown.

Next Steps

With the mix of optimism and concern running through this story, it makes sense to move quickly and evaluate the trade-off for yourself using the 4 key rewards and 3 important warning signs

Looking for more investment ideas?

If you stop with just one stock, you risk missing opportunities that fit your style better, so consider putting a few smart contenders on your radar today.

• Spot potential value opportunities quickly by scanning 46 high quality undervalued stocks that combine quality fundamentals with appealing pricing.
• Build a sturdier core for your portfolio by reviewing solid balance sheet and fundamentals stocks screener (46 results) that focus on financial strength and resilience.
• Get ahead of the crowd by checking screener containing 22 high quality undiscovered gems that highlight under-the-radar companies with strong underlying metrics.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.